Geron Corporation (NASDAQ:GERN – Get Free Report) EVP Timothy Williams purchased 12,000 shares of the stock in a transaction on Monday, November 16th. The shares were purchased at an average price of $0.94 per share, with a total value of $11,280.00. Following the acquisition, the executive vice president owned 12,000 shares in the company, valued at approximately $11,280. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Geron Trading Down 2.6%
Geron stock traded down $0.03 during trading hours on Monday, reaching $0.94. 9,306,519 shares of the company’s stock were exchanged, compared to its average volume of 14,085,533. The firm’s 50 day simple moving average is $1.18 and its 200 day simple moving average is $1.40. Geron Corporation has a twelve month low of $0.84 and a twelve month high of $2.01. The firm has a market capitalization of $606.81 million, a PE ratio of -11.77 and a beta of 0.62. The company has a quick ratio of 4.61, a current ratio of 6.31 and a debt-to-equity ratio of 0.53.
Institutional Trading of Geron
Hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP bought a new stake in shares of Geron during the third quarter valued at approximately $1,406,000. Nantahala Capital Management LLC boosted its stake in shares of Geron by 13.5% during the third quarter. Nantahala Capital Management LLC now owns 13,873,533 shares of the biopharmaceutical company’s stock valued at $17,064,000 after purchasing an additional 1,648,533 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of Geron by 297.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 611,614 shares of the biopharmaceutical company’s stock worth $752,000 after acquiring an additional 457,674 shares in the last quarter. R Squared Ltd increased its holdings in shares of Geron by 52.7% during the third quarter. R Squared Ltd now owns 54,324 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 18,744 shares in the last quarter. Finally, Nan Fung Trinity HK Ltd. lifted its position in Geron by 83.2% during the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 2,223,550 shares of the biopharmaceutical company’s stock worth $2,735,000 after acquiring an additional 1,009,930 shares during the period. Institutional investors own 73.71% of the company’s stock.
Analyst Ratings Changes
A number of equities analysts recently weighed in on GERN shares. Weiss Ratings raised shares of Geron from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, November 9th. Wedbush dropped their price objective on shares of Geron to $5.00 and set an “outperform” rating for the company in a report on Wednesday, October 28th. Finally, Needham & Company LLC reduced their price objective on Geron from $4.00 to $2.50 and set a “buy” rating on the stock in a research note on Wednesday, October 28th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Geron has a consensus rating of “Hold” and a consensus target price of $3.75.
Get Our Latest Stock Report on Geron
Geron Company Profile
Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapies for blood disorders and cancers. Its lead product, Rytelo (imetelstat), is a telomerase inhibitor approved in the United States to treat certain adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. Geron continues to develop imetelstat for potential use in other hematologic conditions. The company was founded in 1990 and is headquartered in Foster City, California.
Recommended Stories
- Five stocks we like better than Geron
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.
